Skip to main content
SpringerLink
Log in

11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aim of this retrospective study was to evaluate the usefulness and the detection rate of 11C-choline PET/CT in a population of patients with prostate cancer (PC), exclusively treated with external beam radiotherapy (EBRT) as primary treatment, who showed biochemical relapse.

Materials and methods

We enrolled 140 patients showing a serum PSA level >2 ng/mL (mean 8.6 ng/mL, median 5 ng/mL, range 2 – 60 ng/mL). All patients had been treated with EBRT to the prostate gland and prostatic fossa with doses ranging from 70 to 76 Gy in low-risk patients (T1/T2 and/or serum PSA <10 ng/mL) and escalating to >76 Gy (range 76 – 81 Gy) in high-risk patients (T3/T4 and/or serum PSA >10 ng/mL). Of the 140 patients, 53 were receiving androgen deprivation therapy at the time of the scan. All positive 11C-choline PET/CT findings were validated by transrectal ultrasound-guided biopsy or at least 12 months of follow-up with contrast-enhanced CT, MR, bone scintigraphy or a repeated 11C-choline PET/CT scan. The relationships between the detection rate of 11C-choline PET/CT and the factors PSA level, PSA kinetics, Gleason score, age, time to relapse and SUVmax in patients with positive findings were analysed.

Results

11C-Choline PET/CT detected the site of relapse in 123 of the 140 patients with a detection rate of 87.8 % (46 patients showed local relapse, 31 showed local and distant relapse, and 46 showed only distant relapse). In patients with relapse the mean serum PSA level was 9.08 ng/mL (median 5.1 ng/mL, range 2 – 60 ng/mL), the mean PSA doubling time was 5.6 months (median 3.5 months, range 0.4 – 48 months), and the mean PSA velocity was 15 ng/mL/year (median 8.8 ng/mL/year, range 0.4 – 87 ng/mL/year). Of the 123 patients with relapse, 77 (62.6 %) showed distant relapse with/without local relapse, and of these 77, 31 (40.2 %) showed oligometastatic disease (one or two distant lesions: lymph node lesions only in 16, bone lesions only in 14, and lymph node lesions and bone lesions in 1). In univariate and multivariate analyses PSA kinetics was the only variable affecting 11C-choline PET/CT detection rate. A significant correlation between PSA kinetics and site of recurrence (local relapse only vs. distant metastasis) was also observed.

Conclusion

The detection rate of 11C-choline PET/CT in patients with PC showing biochemical recurrence after EBRT as primary treatment is relatively high (87.8 %). 11C-Choline PET/CT was able to detect extraprostatic disease in the 62.6 % of patients. Considering this high detection rate, 11C-choline PET/CT could have clinical usefulness in the management of these PC patients, but this should be confirmed in future studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason MD, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.

    Article  PubMed  Google Scholar 

  3. Babaian RJ, Donnelly B, Bahn D, Baust JG, Dineen M, Ellis D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180:1993–2004.

    Article  PubMed  Google Scholar 

  4. Warmuth M, Johansson T, Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur Urol. 2010;58:803–15.

    Article  PubMed  Google Scholar 

  5. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–83.

    Article  PubMed  Google Scholar 

  6. Freedland SJ, Presti Jr JC, Amling CL, Kane CJ, Aronson WJ, Dorey F, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736–41.

    Article  PubMed  Google Scholar 

  7. Kane CJ, Amling CL, Johnstone PAS, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61:607–11.

    Article  PubMed  Google Scholar 

  8. Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179(3):906–10.

    Article  PubMed  Google Scholar 

  9. Fuccio C, Rubello D, Castellucci P, Marzola MC, Fanti S. Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol. 2011;80(2):e50–6.

    Article  PubMed  Google Scholar 

  10. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394–400.

    Article  PubMed  Google Scholar 

  11. Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of 11C-choline-positron emission tomography for re-staging prostate cancer: a comparison with 18F-fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169:1337–40.

    Article  CAS  PubMed  Google Scholar 

  12. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  13. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011;38(1):55–63.

    Article  PubMed  Google Scholar 

  14. Mamede M, Ceci F, Castellucci P, Schiavina R, Fuccio C, Nanni C, et al. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer with very low PSA level <0.5 ng/mL. Clin Nucl Med. 2013;38(9):e342–5.

    Article  PubMed  Google Scholar 

  15. Pascali C, Bogni A, Iwata R. 11C-methylation on 18C SepPak cartridge: a convenient way to produce [N-methyl-11C]choline. J Labelled Compds Radiopharm. 2000;49:195–203.

    Article  Google Scholar 

  16. Khan MA, Carter HB, Epstein JI, Miller MC, Landis P, Walsh PW, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274–8.

    Article  PubMed  Google Scholar 

  17. Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence-free survival rates after external-beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate-specific antigen era: what should we expect? Cancer. 2004;100:1283–92.

    Article  PubMed  Google Scholar 

  18. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11:1066–73.

    Article  CAS  PubMed  Google Scholar 

  19. Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8(2):162–200.

    CAS  PubMed  Google Scholar 

  20. Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60(5):935–43.

    Article  PubMed  Google Scholar 

  21. Tilki D, Reich O, Graser A, Hacker M, Silchinger J, Becker AJ, et al. 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol. 2013;63(5):792–6.

    Article  PubMed  Google Scholar 

  22. Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, et al. Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol. 2013. doi:10.1016/j.urolonc.2013.03.006

  23. Souvatzoglou M, Krause BJ, Pürschel A, Thamm R, Schuster T, Buck AK, et al. Influence of (11)C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99(2):193–200. doi:10.1016/j.radonc.2011.05.005.

    Article  PubMed  Google Scholar 

  24. Würschmidt F, Petersen C, Wahl A, Dahle J, Kretschmer M. [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes. Radiat Oncol. 2011;6:44.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer. 2013;11(1):27–32.

    Article  PubMed  Google Scholar 

  26. Chondrogiannis S, Marzola MC, Ferretti A, Maffione AM, Rampin L, Grassetto G, et al. Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1356–64.

    Article  CAS  PubMed  Google Scholar 

  27. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, et al. Doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37(6):1106–16.

    Article  CAS  PubMed  Google Scholar 

  28. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44(1):32–8.

    Article  PubMed  Google Scholar 

  29. Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37(2):301–9.

    Article  PubMed  Google Scholar 

  30. Martino P, Scattoni V, Galosi AB, Consonni P, Trombetta C, Palazzo S, et al. Role of imaging and biopsy to assess local recurrence after definitve treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol. 2011;29(5):595–605. doi:10.1007/s00345-011-0687-y.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Marcelo Mamede, MD PhD, for his contribution to the final review of the statistical analysis of data and Joshua James Morigi, MD, for his contribution to the language editing.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Service of Nuclear Medicine, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy

    Francesco Ceci, Paolo Castellucci, Tiziano Graziani, Filippo Lodi & Stefano Fanti

  2. Department of Urology, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy

    Riccardo Schiavina, Eugenio Brunocilla & Giuseppe Martorana

  3. Service of Radiotherapy, Policlinico S. Orsola Malpighi, University of Bologna, Bologna, Italy

    Renzo Mazzarotto & Maria Ntreta

  4. UO di Medicina Nucleare, PAD. 30, Azienda Ospedaliero-Unversitaria di Bologna Policlinico Sant’Orsola-Malpighi, Via Massarenti 9, 40138, Bologna, Italy

    Paolo Castellucci

Authors
  1. Francesco Ceci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Castellucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tiziano Graziani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Riccardo Schiavina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eugenio Brunocilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Renzo Mazzarotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maria Ntreta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Filippo Lodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giuseppe Martorana
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stefano Fanti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Castellucci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ceci, F., Castellucci, P., Graziani, T. et al. 11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. Eur J Nucl Med Mol Imaging 41, 878–886 (2014). https://doi.org/10.1007/s00259-013-2655-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-013-2655-9

Keywords

Search

Navigation